Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Arthur C. Houts"'
Publikováno v:
Cancer Research. 78:P4-09
Background: BRCA-mutated breast cancer remains a heterogeneous disease, with variations in histology, response to treatment, and survival outcomes. These cancers are more likely to be negative for estrogen receptor, progesterone receptor, and human e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2039c95fd4cc83172e0e96388bab04c2
https://doi.org/10.1158/1538-7445.sabcs17-p4-09-15
https://doi.org/10.1158/1538-7445.sabcs17-p4-09-15
Autor:
Yousuf Zafar, Nicolas Sommer, Sacha Satram-Hoang, Arthur C. Houts, Joleen M. Hubbard, Sarika Ogale, Mark S. Walker
Publikováno v:
Journal of Gastrointestinal Cancer. 50:16-22
Bevacizumab is a standard first-line (L1) treatment for metastatic colorectal cancer (mCRC) patients regardless of RAS status. This retrospective study examined treatment patterns and outcomes in a community oncology sample of KRAS mutant mCRC patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4f503e4f9321ad6586f21bb584d567d
https://doi.org/10.1007/s12029-017-0017-8
https://doi.org/10.1007/s12029-017-0017-8
Autor:
Gerson Peltz, Mark S. Walker, Arthur C. Houts, Martin Marciniak, Gerhardt Pohl, Lee S. Schwartzberg, Paul J. E. Miller, Edward J. Stepanski
Publikováno v:
Psycho-Oncology. 26:755-762
Background Patients with non-small cell lung cancer (NSCLC) experience adverse physical symptoms because of cancer, cancer treatment, and comorbidities. The relations among Cancer-Related Symptoms, Functional Impairment, and Psychological Symptoms in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0bc2b9aab94c9ab2d8c264f70be02ac
https://doi.org/10.1002/pon.4071
https://doi.org/10.1002/pon.4071
Publikováno v:
Journal of gastrointestinal cancer. 50(1)
Patients with Kirsten rat sarcoma viral oncogene wild-type (KRAS WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) plus standard chemo backbones had comparable outcomes in phase III Cancer and Leukemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a2ea70bb5528f34dca71ffdcc7d71a9
https://pubmed.ncbi.nlm.nih.gov/29168112
https://pubmed.ncbi.nlm.nih.gov/29168112
Publikováno v:
Cancer Treatment and Research Communications. 19:100121
Purpose This retrospective study of community oncology patients with breast cancer gene (BRCA)-mutated metastatic breast cancer (MBC) examined treatment outcomes and health resource utilization (HRU) and costs for a sample of patients with human epid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8048fc3359441c0b2665835a23617d6
https://doi.org/10.1016/j.ctarc.2019.100121
https://doi.org/10.1016/j.ctarc.2019.100121
Autor:
D.M. Chen, Lee S. Schwartzberg, Arthur C. Houts, Mark S. Walker, Carolina M. Reyes, D. D. Ramanan
Publikováno v:
Journal of Cancer Therapy. :24-31
Advanced basal cell carcinoma (aBCC) includes metastatic and locally advanced BCC that is inoperable (or with surgery contraindicated). We describe patient characteristics and treatment history for aBCC cases from community oncology. Nine cases of aB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67cfb07c9859745e77b3d239b4796da6
https://doi.org/10.4236/jct.2013.46a1004
https://doi.org/10.4236/jct.2013.46a1004
Autor:
Edward J. Stepanski, JF Doan, Ls. Schwartzberg, Arthur C. Houts, Walker, M Brammer, Deepa Lalla
Publikováno v:
Cancer Research. 70:P5-12
Background: Trastuzumab (T) is indicated for the adjuvant treatment of HER2-overexpressing breast cancer (BC). We report the results of a retrospective study of patient-reported outcomes (PROs) for patients who received T plus chemotherapy followed b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d9c4ce355427e00602470dc0b2216b
https://doi.org/10.1158/0008-5472.sabcs10-p5-12-04
https://doi.org/10.1158/0008-5472.sabcs10-p5-12-04
Autor:
Edward J. Stepanski, Carolina Reyes, Arthur C. Houts, Mark S. Walker, Johnetta Blakely, Lee S. Schwartzberg
Publikováno v:
Clinical Lung Cancer. 10:426-432
Introduction The purpose of this study was to describe treatment use patterns and outcomes with single-agent erlotinib among patients with advanced Non–Small-cell lung cancer (NSCLC) in the community oncology setting. Patients and Methods Retrospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d15e58b5d79af150f23fc4098c541515
https://doi.org/10.3816/clc.2009.n.080
https://doi.org/10.3816/clc.2009.n.080
Publikováno v:
Psycho-Oncology. 19:399-407
Objective: To evaluate the Patient Care Monitor (PCM1.0) Acute Distress and Despair normalized T scores as indicators of a diagnosis of Major Depression according to the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). Methods: Subje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8edf9b9661d23647d5133ee36b8e3c8d
https://doi.org/10.1002/pon.1583
https://doi.org/10.1002/pon.1583
Autor:
Kimary Kulig, Mark S. Walker, David H. Henry, Lee S. Schwartzberg, Patrick Wayne Cobb, Frank M. Senecal, Edward J. Stepanski, Arthur C. Houts
Publikováno v:
The Breast. 18:78-83
Clinical trials have shown that aromatase inhibitors (AIs) are an important advance in the treatment of early stage breast cancer (ESBC), but practice patterns and the impact of treatment side effects of endocrine therapy in the community setting hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f9a43618285866aff639a675e05d9f
https://doi.org/10.1016/j.breast.2009.01.002
https://doi.org/10.1016/j.breast.2009.01.002